share_log

Tempus AI | 10-Q: Quarterly report

Tempus AI | 10-Q: Quarterly report

Tempus AI | 10-Q:季度報表
美股SEC公告 ·  2024/08/06 16:09

Moomoo AI 已提取核心訊息

Tempus AI, Inc. reported strong revenue growth for Q2 2024, with total revenue increasing 25% year-over-year to $166.0 million. Genomics revenue grew 22% to $112.3 million driven by higher oncology NGS test volumes, while Data and services revenue rose 32% to $53.6 million on increased demand for Insights products. The company completed approximately 66,500 oncology NGS tests in Q2, up from 55,300 in Q2 2023.The company reported a net loss of $552.2 million for Q2 2024, compared to a $55.8 million loss in Q2 2023, primarily due to $488.3 million in stock-based compensation expense recognized upon completion of its June 2024 IPO. Operating expenses increased significantly to $699.5 million from $177.6 million last year, mainly reflecting the IPO-related compensation charges. Adjusted EBITDA loss improved to $31.2 million from $37.0 million in Q2 2023.In June 2024, Tempus completed its IPO, raising net proceeds of $382.0 million through the sale of 11.1 million shares at $37 per share. The company also formed a joint venture in Japan with SoftBank, initially capitalized with ¥30 billion split evenly between the parties. As of June 30, 2024, Tempus had cash and cash equivalents of $479.7 million and total debt of $448.6 million.
Tempus AI, Inc. reported strong revenue growth for Q2 2024, with total revenue increasing 25% year-over-year to $166.0 million. Genomics revenue grew 22% to $112.3 million driven by higher oncology NGS test volumes, while Data and services revenue rose 32% to $53.6 million on increased demand for Insights products. The company completed approximately 66,500 oncology NGS tests in Q2, up from 55,300 in Q2 2023.The company reported a net loss of $552.2 million for Q2 2024, compared to a $55.8 million loss in Q2 2023, primarily due to $488.3 million in stock-based compensation expense recognized upon completion of its June 2024 IPO. Operating expenses increased significantly to $699.5 million from $177.6 million last year, mainly reflecting the IPO-related compensation charges. Adjusted EBITDA loss improved to $31.2 million from $37.0 million in Q2 2023.In June 2024, Tempus completed its IPO, raising net proceeds of $382.0 million through the sale of 11.1 million shares at $37 per share. The company also formed a joint venture in Japan with SoftBank, initially capitalized with ¥30 billion split evenly between the parties. As of June 30, 2024, Tempus had cash and cash equivalents of $479.7 million and total debt of $448.6 million.
Tempus 人工智能公司在2024年第二季度報告了強勁的營業收入增長,總營業收入同比增長25%,達到16600萬美元。基因組學收入增長22%,達到11230萬美元,主要得益於腫瘤學NGS檢測量的增加,而數據及服務收入則增長了32%,達到5360萬美元,受到對Insights產品需求上升的推動。公司在第二季度完成了大約66500個腫瘤學NGS檢測,較2023年第二季度的55300個有所增加。公司在2024年第二季度報告的淨虧損爲55220萬美元,而2023年第二季度的虧損爲5580萬美元,主要是由於在2024年6月完成首次公開募股(IPO)時確認的48830萬美元的股票薪酬費用。營業費用顯著增...展開全部
Tempus 人工智能公司在2024年第二季度報告了強勁的營業收入增長,總營業收入同比增長25%,達到16600萬美元。基因組學收入增長22%,達到11230萬美元,主要得益於腫瘤學NGS檢測量的增加,而數據及服務收入則增長了32%,達到5360萬美元,受到對Insights產品需求上升的推動。公司在第二季度完成了大約66500個腫瘤學NGS檢測,較2023年第二季度的55300個有所增加。公司在2024年第二季度報告的淨虧損爲55220萬美元,而2023年第二季度的虧損爲5580萬美元,主要是由於在2024年6月完成首次公開募股(IPO)時確認的48830萬美元的股票薪酬費用。營業費用顯著增加,從去年的17760萬美元增至69950萬美元,主要反映與IPO相關的薪酬費用。調整後的EBITDA虧損改善至3120萬美元,較2023年第二季度的3700萬美元有所改善。在2024年6月,Tempus完成了首次公開募股,淨籌資38200萬美元,通過以每股37美元出售1110萬股股票進行。該公司還與軟銀在日本成立了一家創業公司,初始資本爲300億日元,由雙方均分。截至2024年6月30日,Tempus的現金及現金等價物爲47970萬美元,總債務爲44860萬美元。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息